Pharmaceutical uses of optically pure (-)-bupropion

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/135 (2006.01) A61K 31/137 (2006.01)

Patent

CA 2318920

Methods and compositions are disclosed utilizing the optically pure (-)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain, bipolar disorders, attention-deficit disorders, conduct disorders, phycho-sexual dysfunction, bulimia, eating disorders or specific food craving. The composition can be administered intravenously, transdermally (patch) or orally, possibily in a sustained release form.

La présente invention concerne des procédés et des compositions dans lesquels on utilise l'(-)-isomère optiquement pur de buproprion, qui est un médicament actif pour traiter la dépression, la maladie de Parkinson, l'obésité, le gain de poids, les troubles déficitaires de l'attention, les troubles bipolaires, le dysfonctionnement psychosexuel, la boulimie, les troubles de l'alimentation ou la fringale d'aliments spécifiques. On peut administrer cette composition de manière intraveineuse, transdermique (timbre) ou oralement, éventuellement sous forme à libération prolongée.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Pharmaceutical uses of optically pure (-)-bupropion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical uses of optically pure (-)-bupropion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical uses of optically pure (-)-bupropion will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1553557

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.